Jacobs Levy Equity Management
VTYX

Jacobs Levy Equity Management’s Ventyx Biosciences VTYX Stock Holding History

Jacobs Levy Equity Management’s Portfolio VTYX Stock Details VTYX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-19,577
Closed -$60.9K – 1069
2025
Q3 		$60.9K Buy
+19,577
New +$51.9K ﹤0.01% 948
2025
Q1 		– Sell
-479,212
Closed -$1.05M – 1210
2024
Q4 		$1.05M Sell
479,212
-89,267
-16% -$202K ﹤0.01% 708
2024
Q3 		$1.24M Buy
568,479
+92,753
+19% +$213K ﹤0.01% 689
2024
Q2 		$1.1M Buy
+475,726
New +$1.98M ﹤0.01% 712

Other funds holding VTYX

AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Jacobs Levy Equity Management's VTYX Position: Q4 2025 in Review

Jacobs Levy Equity Management sold out of Ventyx Biosciences (VTYX) in Q4 2025, closing a stake of 19,577 shares — an estimated $60.9K sold.

Jacobs Levy Equity Management first reported a position in VTYX in Q2 2024 and held it in 4 quarters. The position peaked at $1.24M in Q3 2024. 139 funds tracked by Wall St. Rank hold VTYX as of Q4 2025.

  • Jacobs Levy Equity Management reported no remaining Ventyx Biosciences position as of Q4 2025 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 19,577 Ventyx Biosciences shares in Q4 2025, an estimated $60.9K.
  • Jacobs Levy Equity Management first reported a position in Ventyx Biosciences in Q2 2024 and held it in 4 quarters.
  • Jacobs Levy Equity Management's Ventyx Biosciences position peaked at $1.24M in Q3 2024.
  • 139 funds tracked by Wall St. Rank held Ventyx Biosciences as of Q4 2025.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2025, filed 13 Feb 2026.